Surmodics | SRDX - Equity Capital And Reserves


Surmodics reported $111.31M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Align Technology USD 4.15B 100.27M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Artivion USD 450.47M 2.24M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Boston Scientific USD 25.86B 1.63B Mar/2026
EDAP TMS EUR 23.32M 4.5M Sep/2025
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
Haemonetics USD 796.32M 115.13M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
J&J USD 81.19B 358M Mar/2026
Merit Medical Systems USD 1.63B 42.42M Mar/2026
Mesa Laboratories USD 186.69M 8.22M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Option Care Health USD 1.35B 24.68M Mar/2026
Stryker USD 22.42B 635M Dec/2025
Surmodics USD 111.31M 7.59M Jun/2025
Trinity Biotech USD -54.72M 5.18M Sep/2025